Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (64)	3/20/2001 12:23:31 AM
From: Spekulatius	Respond to of 222

<<Still trying to figure out what I did wrong. >> Probably nothing. You did a bet with due diligence and lost. Bexxar had all the right things going for it: novel mechanism, good clinical data, backup from big pharma - but in the end management wasn't up to the task. There were some signs, that management was not able: First failure of BLA submission, shopping the company around before second BLA submission. Think about the PR spin after the first failed submission "Data formatting etc." now it's almost 2 years later and the drug is still not approved. Sadly,the biggest loosers will be the NHL patients that desperately need the drug.

To: Vector1 who wrote (64)	3/20/2001 12:52:15 AM
From: Pseudo Biologist	Read Replies (2) \| Respond to of 222

Depressing for sure; even though I had made (slightly) worse investments within the last 5 years (no -g-). What did we do wrong? Hard to tell, but I would start with believing in people perhaps we should not have. I agree with Spek, no point hanging around with this company. Bexxar was the only thing worth getting excited about. What do we have to look forward here? PVAC? Good luck to Dr. Gillis and crew. They will need it. PB